| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
AustarPharma, LLC is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.
Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.